Abbott Molecular Inc.
Des Plaines, IL Part of Abbott Laboratories Inc.
- UEI
- NK5QDVJBHMN7
- CAGE
- 44Z73
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Abbott Laboratories Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 334515 Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals
- 334516 Analytical Laboratory Instrument Manufacturing
- 339112 Surgical and Medical Instrument Manufacturing
- 339113 Surgical Appliance and Supplies Manufacturing
- 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- Corporate family
-
-
Parent
Abbott Laboratories Inc. · Lake Bluff, IL
NH3LDK8CFAK7
-
Parent
Abbott Laboratories Inc. · Lake Bluff, IL
NH3LDK8CFAK7
- SAM.gov registration date
- Physical address
- 1300 E Touhy Ave, Des Plaines, IL 60018, USA
- Website
- abbott.com
- Founded
- 1888
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $47,784 |
| FY2026 | $5,718,079 |
| FY2025 | $7,297,383 |
| FY2024 | $73,180 |
| FY2023 | $16,309,856 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $4,116,653 | |
| 2 | Defense Health Agency | $1,239,477 | |
| 3 | Department of Health and Human Services | $409,732 |
Contract vehicles
No active vehicles.
2 expired vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Weems Design Studio, Inc. | 75N91024F00012 | $32,111 | |
| Chemonics International, Inc. | AIDOAATO1500007 | $296,502,479 | |
| Chemonics International, Inc. | AIDOAATO1500007 | $35,570 | |
| Chemonics International, Inc. | AIDOAATO1500007 | $54,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cepheid | Sunnyvale, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Biofire Diagnostics LLC | Salt Lake City, UT | 334516 Analytical Laboratory Instrument Manufacturing |
| Meridian Bioscience Inc. | Cincinnati, OH | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Alere North America LLC | Lake Mary, FL | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Abbott Nutrition | Lake Bluff, IL | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Abbott Molecular Inc., a subsidiary of Abbott Laboratories, manufactures molecular diagnostic reagents, analyzers, and testing supplies for federal healthcare agencies as a prime contractor on full-and-open procurements, with no small business set-asides across its entire recent footprint. Headquartered in Des Plaines, Illinois, Abbott Molecular competes under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) and operates as a large established medical technology corporation without SBA certifications.
Abbott Molecular's federal work centers on molecular diagnostic testing infrastructure. Core capability categories include molecular analyzer equipment, reagents and consumables, specialized probes for fluorescence in situ hybridization (FISH) testing, maintenance and preventative service for installed diagnostic platforms, and cost-per-test arrangements for high-volume infectious disease screening. Representative work includes a $5.8 million definitive contract awarded October 1, 2026, by the Defense Health Agency to supply molecular transplant, respiratory, and sexual health testing services at Brooke Army Medical Center through September 2029 under a cost-per-test model with 300-test-per-shift minimum throughput on FDA-approved multiplex RT-PCR platforms; a $4.5 million delivery order from Veterans Integrated Service Network 5 through October 2029 for Alinity test kits under the GSA Critical Analyzers, Laboratory schedule; and a $8.4 million delivery order from Veterans Integrated Service Network 21 through March 2029 for Alinity M reagents and consumables supporting HIV, hepatitis C, and COVID-19 testing across the VA network.
Customer concentration is heavily weighted to the Department of Veterans Affairs across multiple regional networks. The top five customer agencies by award count account for 35 percent of all awards; by dollar value, the top five account for 27 percent of combined potential value. Veterans Integrated Service Network 2 anchors the portfolio with 78 awards valued at $54.1 million combined potential value; VISN 21 follows with 42 awards at $31.9 million; VISN 20 holds 33 awards at $29.4 million; VISN 9 has 30 awards at $20.2 million; and VISN 19 carries 33 awards at $20.1 million. Outside the VA, Abbott Molecular works with the Centers for Disease Control and Prevention Pittsburgh (51 awards, $5.1 million), the Department of the Army Medical Command (38 awards, $6.7 million), and the Defense Health Agency. Activity has declined from 43 awards in 2022 to 10 awards through October 2026, reflecting market consolidation post-pandemic.
Abbott Molecular holds two dominant GSA Schedule vehicles. The Critical Analyzers, Laboratory (FSS-66-III) schedule carries 185 task orders valued at $102.3 million combined potential value, primarily supporting VA purchasing of test kits, reagents, and maintenance services. The In-Vitro Diagnostics, Reagents, Test (FSS-65-VII) schedule carries 138 task orders valued at $80.6 million combined potential value, similarly anchored to VA molecular diagnostic procurement. Abbott Molecular also holds single-award Blanket Purchase Agreements with individual VISNs—notably a $8.7 million BPA with VISN 2 through May 2027 for Alinity M reagents, a $3.2 million BPA with VISN 19 through November 2026, and a $3.8 million BPA with VISN 6 through April 2029. These BPAs enable task order issuance on an as-needed basis for reagents and consumables supporting the Alinity M platform, which has become a standardized molecular analyzer across the VA healthcare system for infectious disease and clinical laboratory testing.
Award values have shifted markedly. Recent awards trend toward smaller task orders under existing BPAs and GSA Schedule vehicles, with the $5.8 million 2026 DHA contract and the $8.4 million VA delivery order representing upper-range outliers. Twenty-two awards with combined potential value of $13.5 million are scheduled to complete within the next twenty-four months, representing recompete exposure, though the recent activity trajectory suggests incumbent advantage and sustained demand across VISN networks for Alinity platform support. Abbott Molecular maintains near-total reliance on GSA Schedule and VA-direct BPA vehicles; no presence on government-wide contract vehicles like Alliant or OASIS was identified in the source material. The vendor's only identified sub-award carries Abbott Laboratories itself as prime, with Abbott Molecular performing maintenance services for molecular diagnostics analyzers on a National Institute of Allergy and Infectious Diseases contract held by Weems Design Studio.
Quick answers
Is Abbott Molecular Inc. registered in SAM.gov?
Yes. Abbott Molecular Inc.'s SAM.gov registration is active through September 1, 2027.
Which contract vehicles does Abbott Molecular Inc. hold?
Abbott Molecular Inc. holds a place on 2 federal contract vehicles, including FSS-66-III and FSS-65-VII.
How much has Abbott Molecular Inc. received in federal contracts?
Federal contracts obligated $7,297,383 to Abbott Molecular Inc. in fiscal year 2025 and $29,446,281 in fiscal years 2023 through 2027.
How does Abbott Molecular Inc. rank among federal contractors?
Abbott Molecular Inc. ranked #15 in PSC 6550 in FY2025.
What is Abbott Molecular Inc.'s most recent federal award?
Abbott Molecular Inc.'s most recent federal contract award is For molecular transplant, respiratory, and sexual health testing department of pathology and area laboratory services (W81K0025CA008), from Medical Command (Army), on October 1, 2026.
On GovTribe
See Abbott Molecular Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors